Navigation Links
ERK in Medical News

3 newly discovered ERK pathway proteins related to CagA induced disease

Cytotoxin-associated gene A protein (CagA) from type I H.pylori has been proved by epidemiological and experimental studies to be closely associated with the H.pylori induced gastric diseases, especially gastric cancer. However, the precise role of CagA in cell function after H. pylori infection r...

17 of America's Most Promising Scientists Selected as 2009 Pew Scholars in the Biomedical Sciences

...sed on higher-order DNA structure D iana M. Ba u t i sta, Ph. D . U nive r s i ty o f C a l i for n ia, B erk e ley Neuroscience of touch and pain Jon P . B oy l e, Ph. D . U nive r s i ty o f P i t tsb u rgh Hos...

Researchers identify key proteins needed for ovulation

...lular-regulated protein kinases 1 and 2 (ERK 1 and erk 2). In turn, these molecules trigger a chain of c...." While understanding the function of ERK1 and erk 2 may yield important information for treating inf...ce with working versions of the genes for ERK1 and erk 2 were fertile. To date, no other genes have be...

Oncogene inhibits tumor suppressor to promote cancer: Study links B-RAF and LKB1

...bition of B-RAF signaling activated AMPK. The researchers went on to show that LKB1 was phosphorylated by two kinases that are downstream of B-RAF, erk and Rsk. The phosphorylation of LKB1 interfered with the ability of LKB1 to bind and activate AMPK. Importantly, expression of mutant LKB1 that could ...

Protein compels ovarian cancer cells to cannibalize themselves

...lular signaling related kinase, or ERK. Activated erk in the cell nucleus fuels cancer growth. The research team earlier found that PEA-15 binds to erk in the nucleus and moves it out into the cytoplasm...sed on the location of the protein," Ueno said. erk is an inviting target for cancer therapy, Ueno not...

Ardea Biosciences Reports Progress of Clinical Development Programs; Provides 2008 Outlook; Announces 2007 Financial Results and Provides 2008 Financial Guidance

...NNRTI), which is in a Phase 2a study for the treatment of HIV. We are also investigating RDEA806 for the treatment of gout. Our lead mitogen-activated erk kinase (MEK) inhibitor, RDEA119, is in a Phase 1 study in advanced cancer patients and is being investigated for the treatment of inflammatory disease...

Study in Circulation Research details how diabetes drives atherosclerosis

...es of Health. Our experiments found that taking away the SUMO tag from erk protects blood vessels against diabetes, Abe said. We believe that the SUMOylation of erk turns off good genes that are important in countering atherosclerosis. In t...

Oncoproteins double-team and destroy vital tumor-suppressor

...nd DNA damage repair. The team shows in a series of lab experiments that erk attaches phosphate groups to three specific sites on FOXO3a. This phosphory... for destruction by the ubiquitin-proteasome degradation pathway. "Both erk and MDM2 are well-known oncoproteins, but their collaboration was previousl...

Ardea Biosciences' Lead NNRTI for HIV, RDEA806, to Enter Phase 2a Proof-of- Concept Clinical Trial

...iptase inhibitor (NNRTI) for the treatment of HIV, which entered a Phase 2a clinical trial in the fourth quarter of 2007; RDEA119, a mitogen-activated erk kinase (MEK) inhibitor for the treatment of cancer and inflammatory diseases, which is in a Phase 1 clinical trial in advanced cancer patients; and RD...

JCI table of contents: Nov. 15, 2007

...sted that targeting the interaction between CD200 and its receptor might provide a new strategy for the treatment of MM. TITLE: CD200 is induced by erk and is a potential therapeutic target in melanoma AUTHOR CONTACT: Norman E. Sharpless University of North Carolina School of Medicine, Chapel Hil...
ERK in Medical Technology

Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors

- Lead MEK inhibitor, RDEA119, demonstrates potential for once daily oral dosing in preliminary Phase 1 results - - Next generation MEK inhibitor, RDEA436, to enter Phase 1 trials second half of 2008 - SAN DIEGO, April 15 /PRNewswire-FirstCall/ -- Ar...

Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting

...CG) 2008 Annual Meeting in Orlando, Florida. The poster, which provided data from a preclinical study of RDEA119, the Company's lead mitogen-activated erk kinase (MEK) inhibitor, showed the product candidate to be a promising investigational therapy for inflammatory diseases. Oral administration of RDE...

Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at American College of Gastroenterology Annual Scientific Meeting

...FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA ) today announced that preclinical data will be presented on the Company's lead mitogen-activated erk kinase (MEK) inhibitor, RDEA119, at the American College of Gastroenterology Annual Scientific Meeting at the Gaylord Palms Resort & Convention Center...

Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis

... 20 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA ) today announced that data was presented on the Company's lead mitogen-activated erk kinase (MEK) inhibitor, RDEA119, demonstrating potent activity in mouse models of colitis. An oral presentation of the data was given at Digestive Dis...

Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results

...l Research (ICAR); -- Presented preclinical data demonstrating the potent activity and favorable pharmacokinetic profile of our mitogen-activated erk kinase (MEK) inhibitor family of compounds in the treatment of cancer, preliminary Phase 1 data demonstrating the potential for once-daily ...

Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load

...e 2a study for the treatment of HIV. In addition, the Company is investigating RDEA806 for the treatment of gout. The Company's lead mitogen-activated erk kinase (MEK) inhibitor, RDEA119, is in a Phase 1 study in advanced cancer patients and is being investigated for the treatment of inflammatory disease...

Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus

...f HIV. In addition, the Company is also investigating RDEA806 for the treatment of gout. In oncology, the Company is investigating a mitogen-activated erk kinase (MEK) inhibitor, RDEA119, in a Phase 1 study in advanced cancer patients. Ardea also is developing a next-generation NNRTI for HIV and a next-g...

Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout

...se 1 trial in advanced cancer patients with our lead mitogen-activated erk kinase (MEK) inhibitor, RDEA119, in the fourth quarter of 2007; -- A... clinical trial in the fourth quarter of 2007; RDEA119, a mitogen-activated erk kinase (MEK) inhibitor for the treatment of cancer and inflammatory disease...

Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

...oside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV, which recently completed Phase 1 clinical trials, RDEA119, a mitogen-activated erk kinase (MEK) inhibitor for the treatment of cancer and inflammatory diseases, which has been cleared by the FDA to enter Phase 1 clinical trials, and ...

Ardea Biosciences' Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients

...ts. RDEA119 is a highly potent and selective inhibitor of mitogen-activated erk kinase (MEK), a key component of the RAS/RAF/MEK/ERK pathway that is common...ch recently completed Phase 1 clinical trials, RDEA119, a mitogen-activated erk kinase (MEK) inhibitor for the treatment of cancer and inflammatory disease...
ERK in Biological Technology

Detection of Phosphorylated and Total ERK and p38 MAPK by Bio-Plex Assay, ELISA, and Western Blotting, Rev A

Qian Gao, Kris Simonyi, and Claudia Suen, Bio-Rad Laboratories, Inc., 2000 Alfred Nobel Drive, Hercules, CA 94547 USA Introduction Western blotting is a traditional technique for detecting phosphorylated proteins within a variety of c...

Cell Biosciences Introduces Kits for Oncoprotein Analysis

...ed for characterization of proteins in the MEK and erk families, which play critical roles in cancer cell...rug developers have targeted signaling via MEK and erk with a number of kinase inhibitor anticancer drugs...esearchers can obtain detailed profiles of MEK and erk signaling in as few as 25 cells. Subtle effects of...

Ardea Biosciences to Present Data on Gout and Inflammation Programs at the 2008 ACR/ARHP Annual Scientific Meeting

...t preclinical data on RDEA594, its lead product candidate for the treatment of gout, as well as preclinical data on RDEA119,its lead mitogen-activated erk kinase (MEK) inhibitor for the treatment of inflammation associated with gouty arthritis, at the 2008 American College of American College of Rheumato...

Ardea Biosciences to Present Data on Lead MEK inhibitor, RDEA119, at EORTC-NCI-AACR Symposium

...FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA ) today announced that preclinical data will be presented on the Company's lead mitogen-activated erk kinase (MEK) inhibitor, RDEA119, at the 20th European Organisation for Research and Treatment of Cancer (EORTC) -- National Cancer Institute (NCI) -- ...

Ardea Biosciences Presents Inflammation Program Data for Arthritis and Gout at 2008 Annual European Congress of Rheumatology

...nounced that data will be presented on the Company's lead mitogen-activated erk kinase (MEK) inhibitor, RDEA119, demonstrating its potent activity in anima...liferation and the production of inflammatory mediators. Suppression of the erk pathway by inhibitors of MEK1/2 represents a potential therapeutic approach...

Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at Digestive Disease Week 2008

...FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA ) today announced that preclinical data will be presented on the Company's lead mitogen-activated erk kinase (MEK) inhibitor, RDEA119, at Digestive Disease Week (DDW) 2008 in San Diego. The oral presentation details are as follows: Date/Time:...

Ardea Presents Preclinical Data on Novel Next Generation Non-Nucleoside Reverse Transcriptase Inhibitors Demonstrating Potent Anti-HIV Activity Against Resistant Viruses

...e 2a study for the treatment of HIV. In addition, the Company is investigating RDEA806 for the treatment of gout. The Company's lead mitogen-activated erk kinase (MEK) inhibitor, RDEA119, is in a Phase 1 study in advanced cancer patients and is being investigated for the treatment of inflammatory disease...

Ardea to Present Data on HIV Non-Nucleoside Reverse Transcriptase Inhibitor and Two MEK Inhibitors at Upcoming Medical Conferences

...search (ICAR). Additionally, data on two of the Company's mitogen-activated erk kinase (MEK) inhibitors, RDEA119 and RDEA436, will be presented at the Amer...investigating RDEA806 for the treatment of gout. Our lead mitogen-activated erk kinase (MEK) inhibitor, RDEA119, is in a Phase 1 study in advanced cancer p...

Ardea to Present at Cowen and Company's 28th Annual Health Care Conference

...e 2a study for the treatment of HIV. In addition, the Company is investigating RDEA806 for the treatment of gout. The Company's lead mitogen-activated erk kinase (MEK) inhibitor, RDEA119, is in a Phase 1 study in advanced cancer patients and is being investigated for the treatment of inflammatory disease...

Ardea Biosciences to Move Headquarters and R&D Laboratories to San Diego

...e 2a study for the treatment of HIV. In addition, the Company is investigating RDEA806 for the treatment of gout. The Company's lead mitogen-activated erk kinase (MEK) inhibitor, RDEA119, is in a Phase 1 study in advanced cancer patients and is being investigated for the treatment of inflammatory disease...
ERK in Biological Dictionary

Recombinant clone

...ing vector in the lab, it is called a " recombinant DNA ... Anti-phospho-Erk1/2 (Thr202/Tyr204, Thr185/Tyr187), recombinant clone AW39R ... erk 1/2 (Thr202/Tyr204, Thr185/Tyr187), recombinant clone AW39R - DAM1570830 ... Anti-Phosphotyrosine, recombinant clone 4G10®, agarose conjuga...
Other Tags
(Date:4/21/2015)... Dallas, Texas (PRWEB) April 22, 2015 ... Pipeline Review, H1 2015” provides comparative analysis ... The report strengthens R&D pipelines by identifying ... and best-in-class products. Complete report with TOC ... , The report also reviews key players ...
(Date:4/21/2015)... 21, 2015 The joint venture between ... is opening its first freestanding emergency room later this ... and will be licensed under Dignity Health Arizona General ... and Adeptus Health joint venture. , Tim Bricker, President ... Gilbert Medical Centers said the new facility will complement ...
(Date:4/21/2015)... Somerset, NJ & New York, NY (PRWEB) April ... the leading global provider of advanced delivery technologies ... health products, today announced the launch of ADVASEPT™ ... the safe and efficient delivery of injectable medications. ... syringe, combining a safe, convenient and functional container ...
(Date:4/21/2015)... Carinsurancehints.com has released a new blog post ... on auto insurance prices . , Commuting ... Clients should review their insurance options before deciding what ... several forms. Some of the popular policies provide liability, ... online rates and find the best prices in their ...
(Date:4/21/2015)... Colmar, PA (PRWEB) April 21, 2015 ... Ichthyosis & Related Skin Types, Inc.® (FIRST) will publish ... ichthyosis. The campaign will run throughout the month of ... Voice. It Matters to Someone." The positioning was ... about this rare skin disorder and to help support ...
Breaking Medicine News(10 mins):Health News:Pulmonary Embolism Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 2Health News:Pulmonary Embolism Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 3Health News:Pulmonary Embolism Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 4Health News:Dignity Health and Adeptus Health to Open First Freestanding Emergency Room in Chandler, Arizona 2Health News:Dignity Health and Adeptus Health to Open First Freestanding Emergency Room in Chandler, Arizona 3Health News:Catalent Announces the Expansion of its Advanced, Aseptic, Glass-Free Injectable Platform with New ADVASEPT™ Lock Delivery Technology 2Health News:Heavily Circulated Roads Can increase Auto Insurance Costs 2Health News:May is Ichthyosis Awareness Month. Use Your Voice. 2
(Date:3/24/2015)... 24, 2015 Research and Markets ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ) ... - Global Strategic Business Report" report to their offering. ... Biometrics in US$ Thousands by the following Segments: Face Biometrics, and ... Canada , Japan , ... Middle East & Africa , and ...
(Date:3/23/2015)... ANGELES , March 23, 2015  In the ... Federal fraud case conviction losses. This figure accounts for ... which, according to The Nilson Report, exceeds $11 billion ... investigative tool after a crime has occurred. Investor ... and polygraph expert Joe Paolella partnered to ...
(Date:3/20/2015)... , Mar. 19, 2015 Research and Markets ... "Iris Biometrics - Global Strategic Business Report" report to ... for Iris Biometrics in US$ Thousands. The report provides separate ... Japan , Europe , ... , and Latin America . ...
Breaking Biology News(10 mins):Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5
Other Contents